Cidara Therapeutics Company Profile (NASDAQ:CDTX)

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

Cidara Therapeutics, Inc. (NASDAQ:CDTX) announced its earnings results on Wednesday, August, 9th. The company reported ($0.99) EPS for the quarter, missing analysts' consensus estimates of ($0.91) by $0.08. View Cidara Therapeutics' Earnings History.

10 analysts have issued 12-month price objectives for Cidara Therapeutics' shares. Their predictions range from $7.25 to $20.00. On average, they expect Cidara Therapeutics' share price to reach $13.65 in the next twelve months. View Analyst Ratings for Cidara Therapeutics.

Here are some recent quotes from research analysts about Cidara Therapeutics stock:

• 1. According to Zacks Investment Research, "Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. " (8/14/2017)
• 2. Needham & Company LLC analysts commented, "Cidara mgmt provided a corporate update at an Investor Day in NYC last week and we separately hosted a series of mtgs w/ investors. Mgmt reiterated guidance for top-line results from ongoing Phase 2 trial of CD101 in Invasive Candida infections in 4Q17. The trial is expected to serve as the first of two registration trials. Given discontinuation of CD101 Vulvovaginal Candidiasis program, mgmt introduced plans to instead accelerate development in antifungal prophylaxis. KOLs highlighted differentiation from other echinocandins, w/ emphasis on PK/PD profile and opportunity for better clinical outcomes. New details around Cloudbreak candidates were also announced, although clinical testing not expected until 2018. Stock is attractive ahead of Phase 2 CD101 results later this year (EV $15M)." (4/10/2017)
• 3. Cantor Fitzgerald analysts commented, "PD/PK Data Points to Success in Phase 2: Presentations reviewed the potency of CD101 against Candida and Aspergillus species as well as broad and sustained tissue distribution. We found the PK/PD optimized dosing data persuasive as it clearly demonstrates, effective AUC/MIC levels at the 400mg once-weekly over three weeks and 400mg loading dose followed by 200mg once weekly for two weeks, paralleling the two dosing regimens being studied in the Phase 2. We also note the potential for subcutaneous dosing, which could enhance the commercial story. We have increased our probability of success from 45% to 50%. Breadth of Cloudbreak Platform Highlighted: In addition to the antibacterial CD201, currently working through pre-IND studies, early in vivo/in vitro data was presented on a new antifungal asset." (4/7/2017)

Some companies that are related to Cidara Therapeutics include Ardelyx (ARDX), Pieris Pharmaceuticals (PIRS), uniQure N.V. (QURE), Tocagen (TOCA), Chimerix (CMRX), ObsEva SA (OBSV), Immune Design Corp. (IMDZ), Madrigal Pharmaceuticals (MDGL), Kindred Biosciences (KIN), Athersys (ATHX), Zymeworks (ZYME), Faron Pharmaceuticals Oy (FARN), Cascadian Therapeutics (CASC), Aileron Therap (ALRN), Clearside Biomedical (CLSD), Stemline Therapeutics (STML), Kura Oncology (KURA) and XBiotech (XBIT).

Cidara Therapeutics' management team includes the folowing people:

• Scott M. Rocklage Ph.D., Chairman of the Board
• Jeffrey Stein Ph.D., President, Chief Executive Officer, Director
• Matthew W. Onaitis J.D., Chief Financial Officer, Principal Financial Officer, General Counsel, Secretary
• Kenneth Bartizal Ph.D., Chief Development Officer
• Paul Daruwala, Chief Commercial Officer
• Kevin M. Forrest Ph.D., Chief Strategy Officer
• Taylor Sandison M.D., Chief Medical Officer
• Daniel D. Burgess, Director
• Timothy R. Franson M.D., Director
• Robert J. Perez, Director

(CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

Cidara Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (8.76%), InterWest Venture Management Co (8.07%), Frazier Management LLC (7.78%), BB Biotech AG (6.56%), BROADFIN CAPITAL, LLC (5.28%) and PROSIGHT MANAGEMENT, LP (5.20%). Company insiders that own Cidara Therapeutics stock include Jeffrey Stein, Kevin Forrest and Taylor Sandison. View Institutional Ownership Trends for Cidara Therapeutics.

Cidara Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Vanguard Group Inc. and JPMorgan Chase & Co.. View Insider Buying and Selling for Cidara Therapeutics.

Cidara Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Goldman Sachs Group Inc., BB Biotech AG, Susquehanna International Group LLP, Trellus Management Company LLC, LMR Partners LLP, Raymond James Financial Services Advisors Inc. and Citadel Advisors LLC. Company insiders that have bought Cidara Therapeutics stock in the last two years include Jeffrey Stein, Kevin Forrest and Taylor Sandison. View Insider Buying and Selling for Cidara Therapeutics.

Shares of Cidara Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Cidara Therapeutics stock can currently be purchased for approximately $6.75.